Security Snapshot

Keros Therapeutics, Inc. - Common Stock (KROS) Institutional Ownership

CUSIP: 492327101

13F Institutional Holders and Ownership History from Q2 2020 to Q3 2026

13F reference period

Q2 2026

Institutions Reporting

131

Shares (Excl. Options)

18.55MFull value: 18,552,548 · shares · 30 Jun 2026

Price

$10.70

The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Security type / class
Equity / Common Stock
Symbol
KROS on Nasdaq
All holders as of 30 Jun 2026
Q2 2026
Total 13F shares
18,552,548
Latest holder snapshot 5 signals
Total 13F value
$198,558,701
Portfolio coverage rank
0%
Share change
-79,491
Value change
-$984,026
Number of holders
131
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
19,932,637
SEC-reported price per share
$11.64
Insider filing price
$11.64
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • KROS - Keros Therapeutics, Inc. - Common Stock is tracked under CUSIP 492327101.
  • 131 institutions reported positions in Q2 2026.
  • 9 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 148 to 131 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from
    $204.93MFull value: $204,931,904 · USD · 31 Mar 2026
    to
    $198.56MFull value: $198,558,701 · USD · 30 Jun 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 131 institutions filings for Q2 2026.

Open SEC evidence

Security key

492327101

13F reference period

Q2 2026

13F holders

131

13D/G owners

9

CIK / CUSIP context first

Open Q2 2026 holders KROS full holder history Keros Therapeutics, Inc. SEC filings Keros Therapeutics, Inc. company facts Keros Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
9
Security
KROS
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock Portfolio Management LLC 9.1% +57% $20,678,662 +$7,877,562 1,813,870 +62% BlackRock Portfolio Management LLC 30 Sep 2026
BlackRock, Inc. 8.4% -17% $17,883,704 -$3,418,703 1,671,343 -16% BlackRock, Inc. 30 Jun 2026
Nantahala Capital Management, LLC 6.9% $17,073,258 1,360,419 Nantahala Capital Management, LLC 31 Mar 2026
ALKEON CAPITAL MANAGEMENT LLC 2.7% $15,645,210 1,101,000 Alkeon Capital Management LLC 31 Dec 2024
Madison Avenue Partners, LP 2.7% -62% $16,062,286 -$34,918,552 823,707 -68% Madison Avenue International LP 31 Dec 2025
D. E. SHAW & CO, L.P. 3.9% -24% $14,745,042 -$15,400,944 756,156 -51% D. E. Shaw & Co., L.P. 31 Dec 2025
FMR LLC 1.7% $10,010,547 704,472 FMR LLC 31 Jan 2025
JPMORGAN CHASE & CO 0.2% -102% $1,617,141 -$35,146,204 113,803 -96% JPMORGAN CHASE & CO. 30 Apr 2025
ExodusPoint Capital Management, LP 0.04% -104% $260,520 -$36,943,510 13,360 -99% ExodusPoint Capital Management, LP 31 Dec 2025
As of 30 Jun 2026, 131 institutional investors reported holding
18.55MFull value: 18,552,548 · shares · 30 Jun 2026
shares of Keros Therapeutics, Inc. - Common Stock (KROS). This represents 93% of the company’s total
19.93MFull value: 19,932,637 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
75%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 14% 2,794,217 +16% 0% $29,898,120
Nantahala Capital Management, LLC 7.1% 1,410,419 +3.7% 0.91% $15,091,483
AQR CAPITAL MANAGEMENT LLC 4.9% 967,859 +138% 0% $10,356,092
VANGUARD CAPITAL MANAGEMENT LLC 4.2% 833,596 +0.26% 0% $8,919,477
ORBIMED ADVISORS LLC 3.8% 759,155 0% 0.15% $8,122,959
FEDERATED HERMES, INC. 3.5% 700,427 +1.6% 0.01% $7,494,569
VANGUARD PORTFOLIO MANAGEMENT LLC 3.3% 652,635 -4.3% 0% $6,983,195
MACKENZIE FINANCIAL CORP 3.2% 628,438 +312% 0.01% $6,724,287
Madison Avenue Partners, LP 3.1% 626,583 0% 0.29% $6,704,438
Qube Research & Technologies Ltd 3.1% 608,837 -16% 0.01% $6,514,556
JACOBS LEVY EQUITY MANAGEMENT, INC 3% 605,445 -14% 0.02% $6,478,262
STATE STREET CORP 2.7% 541,193 -3.7% 0% $5,790,765
GEODE CAPITAL MANAGEMENT, LLC 2.6% 510,841 -25% 0% $5,467,568
DIMENSIONAL FUND ADVISORS LP 2.3% 460,541 +43% 0% $4,928,290
CITADEL ADVISORS LLC 2% 396,098 -2.6% 0% $4,238,249
RENAISSANCE TECHNOLOGIES LLC 1.8% 359,086 -21% 0.01% $3,842,220
D. E. Shaw & Co., Inc. 1.3% 267,460 -48% 0% $2,861,822
BRIDGEWAY CAPITAL MANAGEMENT, LLC 1.3% 265,017 +36% 0.05% $2,835,682
Nuveen, LLC 1.2% 247,756 -5.5% 0% $2,650,989
ADAR1 Capital Management, LLC 1.2% 246,818 +154% 0.13% $2,640,953
TWO SIGMA INVESTMENTS, LP 1.2% 246,649 -32% 0% $2,639,144
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP 1.2% 233,175 -60% 0% $2,494,973
MILLENNIUM MANAGEMENT LLC 0.93% 184,822 +73% 0% $1,977,595
GOLDMAN SACHS GROUP INC 0.89% 177,846 -21% 0% $1,902,953
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.8% 158,712 -12% 0% $1,698,218

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
26
Headline period
Q2 2026
Rows shown
1-25 of 26
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 840,218 $9,581,756 +$1,347,769 $11.40 20
2026 Q2 18,552,548 $198,558,701 -$984,026 $10.70 131
2026 Q1 18,564,379 $204,931,904 -$29,234,874 $11.04 148
2025 Q4 20,068,584 $408,418,044 -$274,897,076 $20.36 163
2025 Q3 35,272,212 $558,014,186 -$7,638,925 $15.82 151
2025 Q2 35,922,272 $479,567,957 +$53,894,426 $13.35 134
2025 Q1 32,796,190 $334,208,916 -$101,548,195 $10.19 154
2024 Q4 36,741,918 $581,640,265 -$99,583,348 $15.83 159
2024 Q3 34,948,467 $2,029,993,469 +$197,656,348 $58.07 162
2024 Q2 31,483,081 $1,437,735,495 -$1,704,535 $45.70 150
2024 Q1 31,378,208 $2,077,197,760 +$376,189,592 $66.20 144
2023 Q4 25,748,679 $1,023,986,857 +$107,389,201 $39.76 119
2023 Q3 22,915,590 $730,562,303 +$10,983,703 $31.88 106
2023 Q2 22,423,232 $900,980,099 +$13,493,306 $40.18 121
2023 Q1 22,003,238 $936,983,921 +$94,494,039 $42.70 128
2022 Q4 19,814,952 $951,517,038 +$88,887,412 $48.02 122
2022 Q3 18,166,429 $683,394,048 +$33,259,877 $37.62 107
2022 Q2 17,360,328 $479,673,115 +$10,253,619 $27.63 101
2022 Q1 16,425,972 $892,979,574 +$13,785,386 $54.38 101
2021 Q4 16,155,340 $944,400,680 +$68,408,989 $58.51 96
2021 Q3 13,732,777 $543,300,250 -$15,835,150 $39.56 86
2021 Q2 14,120,390 $599,680,759 -$43,588,395 $42.47 79
2021 Q1 14,412,080 $887,014,019 -$122,639,102 $61.55 83
2020 Q4 16,029,747 $1,129,296,879 +$301,336,670 $70.54 81
2020 Q3 11,780,724 $454,579,430 +$33,779,230 $38.57 49
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .